This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
A governance framework for agentic AI assuming clinical functions
-
FDA Grants Breakthrough Device Designation to OraLiva’s Cytology Test for Suspicious Oral Lesions
-
Large language model-assisted chemotherapy side effect management in solid tumor patients: The ALLIANCE randomized controlled trial
Young-Joon Kang, et al..
Weekly News Brief: November 2–6, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of November 2–6, 2026.
This week’s brief covers a governance framework from the AMA on how agentic AI should earn clinical authority, an FDA Breakthrough Device designation granted to a deep learning oral cytology test, and a randomized trial finds LLM support records more chemotherapy toxicities without improving patient outcomes.
To learn more about agentic AI governance, read "AMA Outlines Governance Framework for Agentic AI in Clinical Care," or see the framework.
For more information on ORAL ONC-InCYT, read "Deep Learning Cytology Test for Oral Lesion Assessment Granted FDA Breakthrough Device Designation," or see the press release.
To learn more about the ALLIANCE trial, read "Randomized Trial Finds More Chemotherapy Toxicities Recorded With LLM Assistance but No Patient Benefit," or see the abstract.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.